Vanda Pharmaceuticals (VNDA) Operating Leases (2019 - 2026)

Vanda Pharmaceuticals (VNDA) has 8 years of Operating Leases data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 25.84% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (down 25.84% YoY), and the FY2025 full-year result was $3.0 million, down 39.5% from the prior year.
• Operating Leases improved to $3.3 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.7 million in Q1 2022 to a low of $3.0 million in Q4 2025.
• A 5-year average of $6.5 million and a median of $6.5 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases increased 6.71% in 2023 and slumped 47.43% in 2024, its largest moves.
• Tracing VNDA's Operating Leases over 5 years: stood at $8.8 million in 2022, then gained by 6.71% to $9.4 million in 2023, then slumped by 47.43% to $4.9 million in 2024, then slumped by 39.5% to $3.0 million in 2025, then grew by 9.19% to $3.3 million in 2026.
• Business Quant data shows VNDA's Operating Leases at $3.3 million in Q1 2026, $3.0 million in Q4 2025, and $3.4 million in Q3 2025.